

Organ Preservation in pMMR/MSS Rectal Cancer

1. Kang SB, Cho JR, Jeong SY, et al.: Quality of life after sphincter preservation surgery or abdominoperineal resection for low rectal cancer (ASPIRE): A long-term prospective, multicentre, cohort study. *Lancet Reg Health West Pac* 6:100087, 2021
2. Atallah S, Albert M, Larach S. Transanal minimally invasive surgery: a giant leap forward. *Surg Endosc*. 2010 Sep;24(9):2200-5. doi: 10.1007/s00464-010-0927-z. Epub 2010 Feb 21. PMID: 20174935.
3. Garcia-Aguilar J, Mellgren A, Sirivongs P, Buie D, Madoff RD, Rothenberger DA. Local excision of rectal cancer without adjuvant therapy: a word of caution. *Ann Surg*. 2000 Mar;231(3):345-51. doi: 10.1097/00000658-200003000-00007. PMID: 10714627; PMCID: PMC1421005.
4. Gopaul D, Belliveau P, Vuong T, Trudel J, Vasilevsky CA, Corns R, Gordon PH. Outcome of local excision of rectal carcinoma. *Dis Colon Rectum*. 2004 Nov;47(11):1780-8. doi: 10.1007/s10350-004-0678-9. PMID: 15622569.
5. Lezoche E, Baldarelli M, Lezoche G, Paganini AM, Gesuita R, Guerrieri M. Randomized clinical trial of endoluminal locoregional resection versus laparoscopic total mesorectal excision for T2 rectal cancer after neoadjuvant therapy. *Br J Surg*. 2012 Sep;99(9):1211-8. doi: 10.1002/bjs.8821. PMID: 22864880.
6. Stijns RCH, de Graaf EJR, Punt CJA, Nagtegaal ID, Nuyttens JJME, van Meerten E, Tanis PJ, de Hingh IHJT, van der Schelling GP, Acherman Y, Leijtens JWA, Bremers AJA, Beets GL, Hoff C, Verhoef C, Marijnen CAM, de Wilt JHW; CARTS Study Group. Long-term Oncological and Functional Outcomes of Chemoradiotherapy Followed by Organ-Sparing Transanal Endoscopic Microsurgery for Distal Rectal Cancer: The CARTS Study. *JAMA Surg*. 2019 Jan 1;154(1):47-54. doi: 10.1001/jamasurg.2018.3752. PMID: 30304338; PMCID: PMC6439861.
7. Rullier E, Vendrely V, Asselineau J, Rouanet P, Tuech JJ, Valverde A, de Chaisemartin C, Rivoire M, Trilling B, Jafari M, Portier G, Meunier B, Sieleznieff I, Bertrand M, Marchal F, Dubois A, Pocard M, Rullier A, Smith D, Frulio N, Frison E, Denost Q. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial. *Lancet Gastroenterol Hepatol*. 2020 May;5(5):465-474. doi: 10.1016/S2468-1253(19)30410-8. Epub 2020 Feb 7. PMID: 32043980.
8. Hagen Fritz Kennecke, Christopher J. O'Callaghan, Dongsheng Tu, Roger Leung, Kristopher Dennis, Lisa A. Kachnic, Jonathan M. Loree, Mark Whiteford, William A. Hall, Stacey A. Cohen, Christopher G Cann, Noam Avraham VanderWalde, Steven J. Nurkin, Therese Juul, Winson Y. Cheung, David

Paul Horowitz, Gordon Locke, and Carl J. Brown. The NEO-RT trial: A phase 3 randomized trial of neoadjuvant chemotherapy, excision and observation versus chemoradiotherapy for early rectal cancer, CCTG CO.32. *Journal of Clinical Oncology*. Volume 42, Number 16_suppl doi.org/10.1200/JCO.2024.42.16_suppl.TPS364

9. Habr-Gama A, São Julião GP, Fernandez LM, Vailati BB, Andrade A, Araújo SEA, Gama-Rodrigues J, Perez RO. Achieving a Complete Clinical Response After Neoadjuvant Chemoradiation That Does Not Require Surgical Resection: It May Take Longer Than You Think! *Dis Colon Rectum*. 2019 Jul;62(7):802-808. doi: 10.1097/DCR.0000000000001338. PMID: 31188180.
10. Garcia-Aguilar J, Patil S, Gollub MJ, Kim JK, Yuval JB, Thompson HM, Verheij FS, Omer DM, Lee M, Dunne RF, Marcet J, Cataldo P, Polite B, Herzig DO, Liska D, Oommen S, Friel CM, Ternent C, Coveler AL, Hunt S, Gregory A, Varma MG, Bello BL, Carmichael JC, Krauss J, Gleisner A, Paty PB, Weiser MR, Nash GM, Pappou E, Guillem JG, Temple L, Wei IH, Widmar M, Lin S, Segal NH, Cercek A, Yaeger R, Smith JJ, Goodman KA, Wu AJ, Saltz LB. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. *J Clin Oncol*. 2022 Aug 10;40(23):2546-2556. doi: 10.1200/JCO.22.00032. Epub 2022 Apr 28. PMID: 35483010; PMCID: PMC9362876.
11. Fokas E, Schlenska-Lange A, Polat B, Klautke G, Grabenbauer GG, Fietkau R, Kuhnt T, Staib L, Brunner T, Grosu AL, Kirste S, Jacobasch L, Allgäuer M, Flentje M, Germer CT, Grützmann R, Hildebrandt G, Schwarzbach M, Bechstein WO, Sülberg H, Friede T, Gaedcke J, Ghadimi M, Hofheinz RD, Rödel C; German Rectal Cancer Study Group. Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. *JAMA Oncol*. 2022 Jan 1;8(1):e215445. doi: 10.1001/jamaoncol.2021.5445. Epub 2022 Jan 20. PMID: 34792531; PMCID: PMC8603234.
12. Verheij FS, Omer DM, Williams H, Lin ST, Qin LX, Buckley JT, Thompson HM, Yuval JB, Kim JK, Dunne RF, Marcet J, Cataldo P, Polite B, Herzig DO, Liska D, Oommen S, Friel CM, Ternent C, Coveler AL, Hunt S, Gregory A, Varma MG, Bello BL, Carmichael JC, Krauss J, Gleisner A, Guillem JG, Temple L, Goodman KA, Segal NH, Cercek A, Yaeger R, Nash GM, Widmar M, Wei IH, Pappou EP, Weiser MR, Paty PB, Smith JJ, Wu AJ, Gollub MJ, Saltz LB, Garcia-Aguilar J. Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial. *J Clin Oncol*. 2024 Feb 10;42(5):500-506. doi: 10.1200/JCO.23.01208. Epub 2023 Oct 26. PMID: 37883738.
13. Cerdán-Santacruz C, Vailati BB, São Julião GP, Habr-Gama A, Perez RO. Local tumor regrowth after clinical complete response following neoadjuvant therapy for rectal cancer: what happens when organ preservation falls short. *Tech Coloproctol*. 2023 Jan;27(1):1-9. doi: 10.1007/s10151-022-02654-5. Epub 2022 Aug 20. PMID: 35986804.
14. Chadi SA, Malcomson L, Ensor J, Riley RD, Vaccaro CA, Rossi GL, Daniels IR, Smart NJ, Osborne ME, Beets GL, Maas M, Bitterman DS, Du K, Gollins S, Sun Myint A, Smith FM, Saunders MP, Scott N, O'Dwyer ST, de Castro Araujo RO, Valadao M, Lopes A, Hsiao CW, Lai CL, Smith RK, Paulson EC, Appelt A, Jakobsen A, Wexner SD, Habr-Gama A, Sao Julião G, Perez R, Renehan AG. Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. *Lancet Gastroenterol Hepatol*. 2018 Dec;3(12):825-836. doi: 10.1016/S2468-1253(18)30301-7. Epub 2018 Oct 12. PMID: 30318451.

15. Fernandez LM, São Julião GP, Renehan AG, Beets GL, Papoila AL, Vailati BB, Bahadoer RR, Kranenbarg EM, Roodvoets AGH, Figueiredo NL, Van De Velde CJH, Habr-Gama A, Perez RO; International Watch & Wait Database (IWWD) Consortium. The Risk of Distant Metastases in Patients With Clinical Complete Response Managed by Watch and Wait After Neoadjuvant Therapy for Rectal Cancer: The Influence of Local Regrowth in the International Watch and Wait Database. *Dis Colon Rectum*. 2023 Jan 1;66(1):41-49. doi: 10.1097/DCR.0000000000002494. Epub 2022 Oct 21. PMID: 36515514.
16. São Julião GP, Fernández LM, Vailati BB, Habr-Gama A, Azevedo JM, Santiago IA, Parés O, Parvaiz A, Vendrely V, Rullier A, Rullier E, Denost Q, Perez RO. Local Regrowth and the Risk of Distant Metastases Among Patients Undergoing Watch-and-Wait for Rectal Cancer: What Is the Best Control Group? Multicenter Retrospective Study. *Dis Colon Rectum*. 2024 Jan 1;67(1):73-81. doi: 10.1097/DCR.0000000000002930. Epub

Expanded Access to Hereditary Testing Through Mainstreamed Testing

17. <https://cancer.ca/en/cancer-information/cancer-types/breast/statistics>
18. Sayani, A. Inequities in genetic testing for hereditary breast cancer: implications for public health practice. *J Community Genet*. 2018;10(1):35–39
19. Tutt, A., et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast cancer. *N Engl J Med*. 2021;384:2394-2405.